High‐Throughput Screening for Prescribing Cascades Among Real‐World Angiotensin‐Converting Enzyme Inhibitor Initiators
Identified prescribing cascade signals were indicative of known and possibly underrecognized ACEI adverse events in this Medicare cohort. The findings are hypothesis-generating and require further investigation to determine the extent and impact of the identified PCs on health outcomes.
Authors
- M.-C. Calvet
- Steven M. Smith (ORCID: https://orcid.org/0000-0002-0201-839X)
- Asinamai Ndai (ORCID: https://orcid.org/0000-0002-2517-3915)
- Shailina Keshwani (ORCID: https://orcid.org/0000-0002-9961-2511)
- James H. Hunter (ORCID: https://orcid.org/0000-0003-0877-2104)
- Stephan Schmidt (ORCID: https://orcid.org/0000-0002-4998-1167)
- Carl J. Pepine (ORCID: https://orcid.org/0000-0002-6011-681X)
- Scott Martin Vouri (ORCID: https://orcid.org/0000-0002-0411-2160)
- Shannon Wright (ORCID: https://orcid.org/0000-0002-1751-5444)
- Earl J. Morris (ORCID: https://orcid.org/0000-0002-6092-8906)
- Jaeyoung Choi (ORCID: https://orcid.org/0000-0001-8264-1482)
- Kayla Smith (ORCID: https://orcid.org/0009-0001-7308-5397)
- R. Galvan
- Michael Luvera
- Tanner Beachy
- Matt Molk
Institutions
- Center for Drug Evaluation and Research (US)
- Pfizer (United States) (US)
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/pds.70132
- Citations
- 2
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.45
Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute